Synergism of amphotericin B and 5-fluorocytosine for candida species.

The in vitro activity of amphotericin B and 5-fluorocytosine against 40 isolates of different species of Candida was studied. Synergism was seen in 35 of 40 organisms studied (88%) with achievable serum concentrations of the antibiotics. Synergism was striking in many strains that were resistant to 5-fluorocytosine. When the minimal inhibitory concentration of 5-fluorocytosine was greater than 400 mug/ml, synergism was seen in 18 of 20 isolates of Candida (90%).

[1]  S. Donta,et al.  Effect of 5-fluorocytosine and amphotericin B on Candida albicans infection in mice. , 1974, The Journal of infectious diseases.

[2]  G. Kalmanson,et al.  In Vitro Activity of Ampicillin or Vancomycin Combined with Gentamicin or Streptomycin Against Enterococci , 1973, Antimicrobial Agents and Chemotherapy.

[3]  E. Grunberg,et al.  Chemotherapeutic Activity of 5-Fluorocytosine and Amphotericin B Against Candida albicans in Mice , 1973, Antimicrobial Agents and Chemotherapy.

[4]  S. Shadomy,et al.  In Vitro Activity of 5-Fluorocytosine Against Candida and Torulopsis Species , 1973, Antimicrobial Agents and Chemotherapy.

[5]  P. Hoeprich,et al.  Obfuscation of the activity of antifungal antimicrobics by culture media. , 1972, The Journal of infectious diseases.

[6]  J. E. Johnson,et al.  5-fluorocytosine in the treatment of mycotic infections. , 1972, Annals of internal medicine.

[7]  H. I. Winner,et al.  The development of resistance by candida species to polyene antibiotics in vitro. , 1971, Journal of medical microbiology.

[8]  G. Medoff,et al.  Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-Like Organisms 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  R. Perkins,et al.  5-fluorocytosine in the treatment of cryptococcal and candida mycoses. , 1971, Annals of internal medicine.

[10]  S. Shadomy.  Further In Vitro Studies with 5-Fluorocytosine , 1970, Infection and immunity.

[11]  J. Bennett,et al.  A pharmacologic guide to the clinical use of amphotericin B. , 1969, The Journal of infectious diseases.

[12]  D. E. Rogers,et al.  Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. , 1968, The American journal of medicine.

[13]  D. Louria,et al.  Disseminated moniliasis In the Adult. , 1962 .

[14]  J. Utz,et al.  ANALYSIS OF AMPHOTERICIN TREATMENT FAILURES IN SYSTEMIC FUNGAL DISEASE , 1960, Annals of the New York Academy of Sciences.

[15]  W. Winn.  The use of amphotericin B in the treatment of coccidioidal disease. , 1959, The American journal of medicine.

[16]  T. Sternberg,et al.  Current status of amphotericin B in the treatment of the systemic fungus infections. , 1959, Journal of chronic diseases.

[17]  Louria Db.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man. , 1958 .

[18]  M. Littman,et al.  Coccidioidomycosis and its treatment with amphotericin B. , 1958, American Journal of Medicine.

[19]  M. Pisano,et al.  Induced resistance of Candida species to nystatin and amphotericin B. , 1957, Antibiotics annual.